Janssen Search
Search results
Victories Over Cancer
Article Block Text: Our Cancer Scientists Give Their "Aha!" Moments Article Type: Oncology Research and Innovation This article, written by Ginny Graves, first appeared on jnj.com. One of the biggest health battles the world’s scientists are ...
Dual Perspectives on Digital Twins in Interception Science
Dual Perspectives on Digital Twins in Interception Science In the 1800s, there were several ways to photograph a single image. As image capture was refined, people noticed that successive still photos – or data points – stacked one after another at 10 ...
RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Mar 01, 2024 United States Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT ® plus chemotherapy reduced the risk of disease progression or death by 61 percent versus chemotherapy alone in patients with previously ...
First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration
May 31, 2024 New formulation showed non-inferiority to intravenous administration in fourth positive Phase 3 study in RYBREVANT® clinical program Longer overall survival, progression-free survival and duration of response shown with subcutaneous ...
TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
Jun 14, 2024 24-month overall survival rate of 67 percent achieved with TALVEY® 0.8 mg/kg biweekly dosing in the Phase 1/2 MonumenTAL-1 study MADRID (PRNewswire (June 14, 2024) – Johnson & Johnson (NYSE: JNJ) announced today that long-term data from ...
Living the Principles of Green Chemistry
Living the Principles of Green Chemistry Our series on green chemistry continues with an exploration of how we at Janssen approach and activate these vital principles. Click here for a primer on green chemistry, and watch this space for additional ...
Igniting Positive Change: A Story for International Women’s Day 2020
Igniting Positive Change: A Story for International Women’s Day 2020 I carpool with a colleague, Brenda. She and I work in different areas of R&D, grew up on different continents and have different tastes in food. But, despite our diverse ...
U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)
Mar 22, 2024 United States OPSYNVI ® combines two proven treatments with established efficacy and safety profiles into one tablet to be taken once daily, offering an option that helps to support the implementation of clinical guideline recommendations for ...
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Erdafitinib for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer with Susceptible FGFR Alterations
Sep 08, 2023 Belgium Pending approval, erdafitinib, an investigational, once-daily oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, [1] will become the first therapy targeting FGFR alterations [2] in patients with metastatic ...
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer
Aug 20, 2024 United States RYBREVANT ® plus LAZCLUZE™ is the first and only chemotherapy-free regimen showing superior progression-free survival versus osimertinib Following Priority Review, approval is based on Phase 3 MARIPOSA results showing RYBREVANT ...